ATE394124T1 - Verfahren, zusammensetzungen und herstellungsgegenstände zur modulierung des knochenwachstums - Google Patents
Verfahren, zusammensetzungen und herstellungsgegenstände zur modulierung des knochenwachstumsInfo
- Publication number
- ATE394124T1 ATE394124T1 AT03727927T AT03727927T ATE394124T1 AT E394124 T1 ATE394124 T1 AT E394124T1 AT 03727927 T AT03727927 T AT 03727927T AT 03727927 T AT03727927 T AT 03727927T AT E394124 T1 ATE394124 T1 AT E394124T1
- Authority
- AT
- Austria
- Prior art keywords
- bone growth
- methods
- articles
- compositions
- manufacture
- Prior art date
Links
- 230000008468 bone growth Effects 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 208000020084 Bone disease Diseases 0.000 abstract 1
- 102000018208 Cannabinoid Receptor Human genes 0.000 abstract 1
- 108050007331 Cannabinoid receptor Proteins 0.000 abstract 1
- 210000002449 bone cell Anatomy 0.000 abstract 1
- 230000010072 bone remodeling Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000003405 preventing effect Effects 0.000 abstract 1
- 238000007634 remodeling Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH] (Somatotropin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/553—Renin inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38588102P | 2002-06-06 | 2002-06-06 | |
US41027602P | 2002-09-13 | 2002-09-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE394124T1 true ATE394124T1 (de) | 2008-05-15 |
Family
ID=33479219
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT03727927T ATE394124T1 (de) | 2002-06-06 | 2003-06-08 | Verfahren, zusammensetzungen und herstellungsgegenstände zur modulierung des knochenwachstums |
Country Status (7)
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7024027B1 (en) * | 2001-11-13 | 2006-04-04 | Koninklijke Philips Electronics N.V. | Method and apparatus for three-dimensional filtering of angiographic volume data |
JP2006517194A (ja) * | 2002-06-06 | 2006-07-20 | イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティ オブ エルサレム | 骨成長を調節するための方法、組成物および製造物 |
WO2004058145A2 (en) * | 2002-12-19 | 2004-07-15 | Merck & Co., Inc. | Substituted amides |
US7407753B2 (en) | 2004-05-24 | 2008-08-05 | Yissum Research Development Company Of The Hebrewuniversityofjerusalem | Methods, kits and pharmaceutical compositions for diagnosing, delaying onset of, preventing and/or treating osteoporosis |
NO20053519L (no) * | 2005-07-18 | 2007-01-19 | Thia Medica As | Anvendelse av forbindelser som omfatter fettsyrer |
WO2008001369A1 (en) * | 2006-06-27 | 2008-01-03 | Pharmos Corporation | Use of cb2 receptor agonists for promoting neurogenesis |
WO2008033501A2 (en) * | 2006-09-14 | 2008-03-20 | Spineology, Inc. | Absorbent fabric implant |
EP2268301B1 (en) * | 2008-01-24 | 2020-02-26 | Remedor Biomed Ltd. | Erythropoietin and fibronectin compositions for bone regeneration |
GB0808668D0 (en) * | 2008-05-13 | 2008-06-18 | Univ Aberdeen | Materials and methods relating to a G-protein coupled receptor |
WO2010041253A1 (en) | 2008-10-06 | 2010-04-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. | Compositions comprising cb receptor agonists, uses thereof and methods for their preparation |
TWI443337B (zh) * | 2008-10-10 | 2014-07-01 | Ct Hospitalier Universitaire Sainte Justine | 用於脊柱側彎之分類及診斷的方法 |
US8541386B2 (en) * | 2009-08-19 | 2013-09-24 | University Of South Florida | Cannabinoid 2 (CB2) receptor gene promoter and unique RNA transcripts in B cells and methods of use |
US10413253B2 (en) * | 2014-11-21 | 2019-09-17 | Samsung Electronics Co., Ltd. | Method and apparatus for processing medical image |
US9585867B2 (en) | 2015-08-06 | 2017-03-07 | Charles Everett Ankner | Cannabinod formulation for the sedation of a human or animal |
KR102002817B1 (ko) * | 2017-10-25 | 2019-07-23 | 주식회사 시티오브테크 | 방수 아스콘 첨가제 및 그 제조방법, 방수 아스콘 및 그 제조방법 그리고, 방수 아스콘 시공방법 |
AU2019278992A1 (en) * | 2018-05-31 | 2020-12-17 | Corbus Pharmaceuticals Inc. | Cannabinoids and uses thereof |
US11793452B2 (en) | 2019-10-03 | 2023-10-24 | Johnson & Johnson Consumer Inc. | Method of visualizing and quantifying remineralization |
KR20220138990A (ko) * | 2021-04-07 | 2022-10-14 | 주식회사 스템바이오 | 우유 유래 세포외소포체를 포함하는 골형성 촉진용 조성물 |
CN114748604B (zh) * | 2022-05-10 | 2023-04-07 | 四川大学 | 一种用于骨髓损伤和/或抑制的复合物 |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5068234A (en) | 1990-02-26 | 1991-11-26 | Sterling Drug Inc. | 3-arylcarbonyl-1-(c-attached-n-heteryl)-1h-indoles |
CA2040264A1 (en) | 1990-04-12 | 1991-10-13 | Tatsuhiko Kanmera | Parathyroid hormone antagonists |
US5225925A (en) | 1991-01-23 | 1993-07-06 | Amoco Corporation | Sensitized erbium fiber optical amplifier and source |
US5208219A (en) | 1991-02-14 | 1993-05-04 | Celtrix Pharmaceuticals Inc. | Method for inducing bone growth |
ATE139700T1 (de) | 1991-02-15 | 1996-07-15 | Takeda Chemical Industries Ltd | Mit einem zellwachstumsfaktor bewirkte anregung von wachstum im knocheninneren |
FR2673852B1 (fr) | 1991-03-13 | 1994-04-15 | Labinal Precision Mecanique | Perfectionnements apportes aux cartouches de filtration comprenant un element filtrant constitue par une feuille plissee. |
IL101927A0 (en) | 1992-05-19 | 1992-12-30 | Yissum Res Dev Co | Probe for cannabinoid receptors |
IL103932A (en) | 1992-11-30 | 1997-02-18 | Yissum Res & Dev | Fatty acid and pharmaceutical compositions containing them |
US6352972B1 (en) | 1995-06-06 | 2002-03-05 | Marcel E. Nimni | Bone morphogenetic proteins and their use in bone growth |
US6352973B1 (en) | 1995-06-07 | 2002-03-05 | Osteopharm Inc. | Bone stimulating factor |
US6008208A (en) | 1995-10-23 | 1999-12-28 | Osteoscreen, Inc. | Compositions and methods for treating bone deficit conditions |
US6440421B1 (en) | 1996-04-18 | 2002-08-27 | Auchkland Uniservices Limited | Treatment of bone disorders with adrenomedullin or adrenomedullin agonists |
US5688825A (en) | 1996-05-31 | 1997-11-18 | University Of Connecticut | Anandamide amidase inhibitors as analgesic agents |
WO1998031227A1 (en) * | 1997-01-21 | 1998-07-23 | Smithkline Beecham Corporation | Novel cannabinoid receptor modulators |
FR2758723B1 (fr) | 1997-01-28 | 1999-04-23 | Sanofi Sa | Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments |
DE19706903A1 (de) | 1997-02-21 | 1998-08-27 | Bayer Ag | Verwendung von bekannten Agonisten des zentralen Cannabinoid-Rezeptors CB 1 |
WO1998041519A1 (en) * | 1997-03-18 | 1998-09-24 | Smithkline Beecham Corporation | Novel cannabinoid receptor agonists |
WO1999026612A1 (en) * | 1997-11-21 | 1999-06-03 | Smithkline Beecham Corporation | Novel cannabinoid receptor modulators |
ES2209417T3 (es) | 1998-04-03 | 2004-06-16 | Yissum Research And Development Company Of The Hebrew University Of Jerusalem | Analogos de los cannabinoides endogenos sinteticos y sus usos. |
EP1076653B1 (en) | 1998-05-04 | 2004-09-29 | The University of Connecticut | Novel cannabinoids selective for the cb2 receptor |
US6462019B1 (en) | 1998-07-10 | 2002-10-08 | Osteoscreen, Inc. | Inhibitors of proteasomal activity and production for stimulating bone growth |
AU4013500A (en) | 1999-07-28 | 2001-02-19 | Ewonders.Com | Dynamic data gathering markup language |
CA2399791A1 (en) | 2000-02-11 | 2001-08-16 | Bristol-Myers Squibb Company | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases |
US6448288B1 (en) | 2000-05-17 | 2002-09-10 | University Of Massachusetts | Cannabinoid drugs |
DE60106026T2 (de) | 2000-06-23 | 2006-02-23 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | 2-arachidonylglycerol (2-ag)-ein hemmer des tumor nekrose faktors-alfa und neuroprotektor des gehirns bei geschlossenen kopfverletzungen |
FR2816938B1 (fr) * | 2000-11-22 | 2003-01-03 | Sanofi Synthelabo | Derives de 3-aroylindole, leur procede de preparation et les compositions pharmaceutiques en contenant |
US20020077322A1 (en) | 2000-12-15 | 2002-06-20 | Ayoub George S. | Protection of neurons against glutamate-induced damage in glaucoma and other conditions |
US20020111377A1 (en) | 2000-12-22 | 2002-08-15 | Albany College Of Pharmacy | Transdermal delivery of cannabinoids |
CA2443105C (en) * | 2001-04-06 | 2011-11-08 | The Board Of Trustees Of The University Of Illinois | Functional role for cannabinoids in autonomic stability during sleep |
JP2006517194A (ja) * | 2002-06-06 | 2006-07-20 | イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティ オブ エルサレム | 骨成長を調節するための方法、組成物および製造物 |
EP1606019A1 (en) * | 2003-03-07 | 2005-12-21 | The University Court of The University of Aberdeen | Cannabinoid receptor inverse agonists and neutral antagonists as therapeutic agents for the treatment of bone disorders |
-
2003
- 2003-06-08 JP JP2004572061A patent/JP2006517194A/ja active Pending
- 2003-06-08 AT AT03727927T patent/ATE394124T1/de not_active IP Right Cessation
- 2003-06-08 WO PCT/IL2003/000480 patent/WO2004103410A1/en active IP Right Grant
- 2003-06-08 DE DE60320784T patent/DE60320784D1/de not_active Expired - Lifetime
- 2003-06-08 EP EP03727927A patent/EP1509250B1/en not_active Expired - Lifetime
- 2003-06-08 AU AU2003233172A patent/AU2003233172A1/en not_active Abandoned
-
2004
- 2004-12-06 US US11/003,939 patent/US7749953B2/en not_active Expired - Fee Related
-
2010
- 2010-02-23 US US12/710,540 patent/US20100222438A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US7749953B2 (en) | 2010-07-06 |
DE60320784D1 (de) | 2008-06-19 |
JP2006517194A (ja) | 2006-07-20 |
EP1509250A4 (en) | 2005-08-17 |
US20050137159A1 (en) | 2005-06-23 |
AU2003233172A1 (en) | 2004-12-13 |
US20100222438A1 (en) | 2010-09-02 |
EP1509250B1 (en) | 2008-05-07 |
WO2004103410A1 (en) | 2004-12-02 |
EP1509250A1 (en) | 2005-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE394124T1 (de) | Verfahren, zusammensetzungen und herstellungsgegenstände zur modulierung des knochenwachstums | |
DE602004017736D1 (de) | Verwendung von rapamycin und dessen derivaten zur behandlung von knochenverlust | |
DE602004014117D1 (de) | Thiazole zur verwendung als inhibitoren von protein-kinasen | |
JO2481B1 (en) | Silo cano-indol compounds have fluoride substitution and formulations containing such compounds and their treatment methods | |
DE602004031134D1 (de) | Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa | |
BR0315689A (pt) | Alvo para terapia de dano cognitivo | |
MEP90508A (en) | New pharmaceutical composition | |
DK0725790T3 (da) | Substituerede tetra- og pentapeptidinhibitorer af proteinfarnesyltransferase | |
DE60335743D1 (de) | Verbindungen und verfahren zur erhöhung der neurogenese | |
ATE443043T1 (de) | Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer | |
DE602005026556D1 (de) | Zusammensetzung zur proteasomhemmung | |
ATE311363T1 (de) | Sulfohydroxamsäure and sulfohydroxamate und ihre verwendung als mek-inhibitoren | |
WO2003103581A3 (en) | COMPOSITIONS AND METHODS FOR LIVER GROWTH AND PROTECTION | |
DE602005026866D1 (de) | Vewendung von dreidimensionalem kultiviertem gewebe zur behandlung von kongestivem herzversagen | |
BRPI0414598A (pt) | indóis substituìdos | |
DE69905476T2 (de) | Phosphonsaürederivate als ptp-1b-inhibitoren | |
MA27880A1 (fr) | Derives de tetrahydrocarbazole et leur utilisation pharmaceutique | |
ATE448775T1 (de) | Rifalazil zur behandlung von infektionen mit clostridium difficile | |
ATE421574T1 (de) | Zellkulturmethode zur erzeugung von prostata- ähnlichen acini | |
ATE302002T1 (de) | Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit | |
ATE423110T1 (de) | Verbindungen, zusammensetzungen und verfahren zur behandlung von zellulären proliferativen erkrankungen | |
MXPA03007413A (es) | Composicion y metodo para tratar enfermedades inflamatorias. | |
ATE443044T1 (de) | Tace inhibitoren | |
ATE290857T1 (de) | Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen | |
DE60322064D1 (de) | 4,4' -dithiobis- (3-aminobutane-1-sulfonate)-derivate und sie enthaltende zusammensetzungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |